Name : DUMMY Collected : 29/8/2017 12:00:00AM

Lab No. : 135091667 Age: 37 Years Gender: Male Received : 29/8/2017 10:01:29AM Reported : 29/8/2017 11:38:51AM

A/c Status : P Ref By : Dr. UNKNWON Report Status : Final

Test Name Results Units Bio. Ref. Interval

COAGULATION PROFILE 1

PARTIAL THROMBOPLASTIN TIME, ACTIVATED; APTT

(Photo optical Clot Detection)

Patient Value 25.70 sec 23.57 - 29.33

Control Value 25.70 sec

Note

Degree of prolongation of PTT / APTT is neither predictive of bleeding risk nor underlying diagnosis

- Results should be clinically correlated
- 3. Test conducted on Citrated plasma

Comments

Partial Thromboplastin time (PTT / APTT) measures the proteins of the intrinsic coagulation pathway which consists of Factor XII, Prekallikrein, High molecular weight kininogen, Factors VIII, IX & XI. It also measures proteins of the common pathway namely factors II, V, X & Fibrinogen. PTT is prolonged when Factor VIII level is < 35-40% of normal and Factor XII & High molecular weight kininogen is < 10-15% of normal.

Abnormal Partial Thromboplastin Time

- Associated with bleeding: Defects of factors VIII, IX & XI
- Not associated with bleeding: Defects of factor XII, Prekallikrein, High molecular weight kininogen & Lupus anticoagulants

Causes of prolonged PTT / APTT

- Liver disease
- Consumptive coagulopathy
- · Circulating anticoagulants including Lupus Anticoagulant
- Oral Anticoagulant therapy
- Factor deficiencies

PROTHROMBIN TIME STUDIES

(Photo optical Clot Detection)

Mean Normal Prothrombin Time (PT) 10.30 sec <10.70



Name : DUMMY Collected : 29/8/2017 12:00:00AM

Lab No. : 135091667 Age: 37 Years Gender: Male Received : 29/8/2017 10:01:29AM Reported : 29/8/2017 11:38:51AM

A/c Status : P Ref By : Dr. UNKNWON Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
Patient value	10.30	sec	9.57 - 11.80
Prothrombin Ratio (PR)	1.00		
International Normalized Ratio (INR)	1.00		0.90 - 1.10

Note

- 1. INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity
- 2. Prolonged INR suggests potential bleeding disorder / bleeding complications
- 3. Results should be clinically correlated
- 4. Test conducted on Citrated plasma

Recommended Therapeutic range for Oral Anticoagulant therapy

INR 2.0-3.0:

- Treatment of Venous thrombosis & Pulmonary embolism
- Prophylaxis of Venous thrombosis (High risk surgery)
- Prevention of systemic embolism in tissue heart valves, AMI, Valvular heart disease & Atrial fibrillation
- Bileaflet mechanical valve in aortic position

INR 2.5-3.5:

- Mechanical prosthetic valves
- Systemic recurrent emboli

Comments

Prothrombin time measures the extrinsic coagulation pathway which consists of activated Factor VII (VIIa), Tissue factor and Proteins of the common pathway (Factors X, V, II & Fibrinogen). This assay is used to control long term oral anticoagulant therapy, evaluation of liver function & to evaluate coagulation disorders specially factors involved in the extrinsic pathway like Factors V, VII, X, Prothrombin & Fibrinogen.

THROMBIN TIME; TT (Electromechanical Clot Detection)			
Patient Value	16.90	sec	<21.00
Control Value	16.90	sec	15.00 - 21.00

Note

1. Thrombin Time should be interpreted in conjunction with other coagulation assays like PT &



Name : DUMMY Collected : 29/8/2017 12:00:00AM

Lab No. : 135091667 Age: 37 Years Gender: Male Received : 29/8/2017 10:01:29AM Reported : 29/8/2017 11:38:51AM

A/c Status : P Ref By : Dr. UNKNWON Report Status : Final

Test Name Results Units Bio. Ref. Interval

APTT to enhance diagnostic value.

2. Results should be clinically correlated.

3. Test conducted on Citrated plasma.

Comments

Thrombin Time (TT) measures the ability of exogenous thrombin to proteolyse fibrinogen. Thus it is used to characterize fibrinogen function. It is prolonged in conditions like hypofibrinogenemia, dysfibrinogenemia, presence of fibrin degradation products, antibody inhibitors of thrombin and in conditions with high concentrations of monoclonal immunoglobulins which interfere with fibrin monomer polymerization like Myeloma & Macroglobulinemia.

BLEEDING TIME; BT # (Ivy's Method)	2.00	minutes	2 - 7
CLOTTING TIME; CT # (Lee & White)	5.00	minutes	3 - 10

Note: Recommended test is Prothrombin Time (PT) and Activated Partial Thromboplastin time (APTT)



Name : DUMMY Collected : 29/8/2017 12:00:00AM

Lab No. : 135091667 Age: 37 Years Gender: Male Received : 29/8/2017 10:01:29AM Reported : 29/8/2017 11:38:51AM

A/c Status : P Ref By : Dr. UNKNWON Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
COMPLETE BLOOD COUNT (CBC) (Electrical Impedance & VCS,Photometry)			
Hemoglobin	11.50	g/dL	13.00 - 17.00
Packed Cell Volume (PCV)	35.40	%	40.00 - 50.00
RBC Count	4.16	mill/mm3	4.50 - 5.50
MCV	85.20	fL	80.00 - 100.00
MCH	27.60	pg	27.00 - 32.00
MCHC	32.40	g/dL	32.00 - 35.00
Red Cell Distribution Width (RDW)	16.10	%	11.50 - 14.50
Total Leukocyte Count (TLC)	7.10	thou/mm3	4.00 - 10.00
Differential Leucocyte Count (DLC)			
Segmented Neutrophils	56.70	%	40.00 - 80.00
Lymphocytes	27.30	%	20.00 - 40.00
Monocytes	14.40	%	2.00 - 10.00
Eosinophils	1.00	%	1.00 - 6.00
Basophils	0.60	%	<2.00
Absolute Leucocyte Count			
Neutrophils	4.03	thou/mm3	2.00 - 7.00
Lymphocytes	1.94	thou/mm3	1.00 - 3.00
Monocytes	1.02	thou/mm3	0.20 - 1.00
Eosinophils	0.07	thou/mm3	0.02 - 0.50
Basophils	0.04	thou/mm3	0.01 - 0.10
Platelet Count	273.0	thou/mm3	150.00 - 450.00

Note

- As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood
- 2. Test conducted on EDTA whole blood



Name : DUMMY

Lab No. : 135091667 Age: 37 Years Gender: Male Received : 29/8/2017 10:01:29AM Reported : 29/8/2017 11:38:51AM

A/c Status : P Ref By : Dr. UNKNWON Report Status : Final

Test Name Results Units Bio. Ref. Interval

Dr. Anil Arora MD (Pathology) HOD Hemat & Imm

Dr Biswadip Hazarika MD (Pathology) Sr. Consultant Pathologist

----End of report --

: 29/8/2017 12:00:00AM

Collected